EFFICACY AND SAFETY EVALUATION OF A REGIMEN CONSISTING OF PEGINTERFERON LAMBDA-1A + RIBAVIRIN + DACLATASVIR (LAMBDA + RBV + DCV) IN HCV GENOTYPE 1B TREATMENT NAÏVE PATIENTS OR PRIOR RELAPSERS TO PEGINTERFERON ALFA + RIBAVIRIN (ALFA + RBV) THERAPY: